Recent investigations have focused on the convergence of GLP-1|GIP|glucagon receptor activator therapies and dopaminergic signaling. While GLP agonists are increasingly employed for managing type 2 T2DM, their potential effects on reinforcement circuits, specifically mediated by DA pathways, are attracting significant interest. This report details